Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Pureos Partners AG. (1/17/23). "Press Release: Pureos Partners Welcomes Dr. Ulf Grawunder to Its Team as Venture Partner". Pfäffikon.

Organisations Organisation Pureos Partners AG
  Group Bellevue (Group)
  Organisation 2 NBE Therapeutics AG
  Group Boehringer Ingelheim (Group)
Products Product venture capital
  Product 2 BIOTECH
Persons Person Grawunder, Ulf (T-Curx 202210– CEO + Co-Founder before NBE Therapeutics + 4-Antibody)
  Person 2 Escher, Dominik (Belleveue 201001 Managing Partner at BB Pureos Bioventures before ESBATech CEO + Founder)

Pureos Partners (Pureos), a venture capital firm dedicated to support private biotech companies developing novel therapies, announced the appointment of Dr. Ulf Grawunder as Venture Partner to its team. The fund has USD 205 million under management and has invested in 18 private biotech companies to date. Three portfolio companies have already gone public or have been acquired.

Dr. Ulf Grawunder will support Pureos as a new Venture Partner. Ulf is a highly successful serial entrepreneur. He was founder and CEO of several biotech companies including NBE-Therapeutics, a Swiss company developing novel antibody drug conjugates for cancer therapies. Ulf successfully sold the company for USD 1.4 billion to Boehringer Ingelheim in 2021. Since then, Ulf has co-founded T-CURX, a biotech company developing novel cell therapies for cancer treatments. Ulf is a biochemist by training and received his PhD from the Basel Institute for Immunology. During his academic career, he worked at Washington University School of Medicine (USA), the University of Southern California (USA) and the Basel Institute for Immunology. Ulf also holds a Diploma of Technology Entrepreneurship from the University St. Gallen.

Commenting on his appointment as Venture Partner, Ulf said: ”I am very excited to support Pureos. I have known the fund and the people involved for many years and I am impressed by the quality of the team and their investments. Pureos plays a very important role for early-stage biotech companies, especially in Switzerland where the fund has supported multiple company creations and has led several early-stage financing rounds. With my experience of starting, building and selling biotech companies, I am very excited to contribute to the future success of the Pureos portfolios.”

Managing Partner of Pureos, Dominik Escher stated: “We are all very pleased to welcome Ulf as Venture Partner at Pureos. Ulf brings an outstanding entrepreneurial experience in the biotech sector. This will help our existing and future portfolio companies to better grow and develop novel treatments for patients in need.”


About Pureos Bioventures

Pureos Partners is a Swiss venture capital firm and the investment adviser of Pureos Bioventures. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

For more information visit


Dr. Klaus Breiner

Dr. Dominik Escher

Dr. Veronica Gambillara Fonck

Dr. Martin Münchbach

Pureos Partners AG
Churerstrasse 47
8808 Pfäffikon/SZ

Record changed: 2024-01-20


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Bellevue (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top